Frederick G. Vogt - 02 Mar 2026 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role: Interim CEO & General Counsel, Director
Signature: /s/ Frederick G. Vogt
Issuer symbol: IOVA
Transactions as of: 02 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 04 Mar 2026, 17:01:44 UTC
Previous filing: 03 Dec 2025
Next filing: 06 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Vogt Frederick G	Interim CEO & General Counsel, Director	C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, SUITE 100, SAN CARLOS	/s/ Frederick G. Vogt	04 Mar 2026	0001719678

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IOVA	Common Stock	Options Exercise		+52,087	+11%	$0.000000^*	516,609	02 Mar 2026	Direct	F1
transaction	IOVA	Common Stock	Tax liability		-22,809	-4.4%	$3.79^*	493,800	02 Mar 2026	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IOVA	Restricted Stock Units	Options Exercise		-41,669	-20%	$0.000000^*	166,675	02 Mar 2026	Common stock	41,669		Direct	F4, F5, F6
transaction	IOVA	Restricted Stock Units	Options Exercise		-10,418	-100%	$0.000000^*	0	02 Mar 2026	Common stock	10,418		Direct	F4, F5, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
F2	Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
F3	Represents common stock remaining after deducting the common stock withheld for taxes.
F4	Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5	The remaining RSUs will vest in equal quarterly installments.
F6	Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.
F7	Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person.